Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales

Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Press Trust of India New Delhi
1 min read Last Updated : May 29 2021 | 9:58 PM IST

Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales.

The company had posted a net profit of Rs 388.23 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a regulatory filing.

Consolidated total income of the company stood at Rs 1,811.71 crore for the quarter under consideration. It was Rs 1,466.44 crore for the same period a year ago, it added.

For the fiscal year ended March this year, the company posted a net profit of Rs 1,984.29 crore as against Rs 1,376.54 crore for the previous fiscal year, the filing said.

The company's total income for the financial year ended March 2021 stood at Rs 7,031.96 crore. It was Rs 5,584.05 crore for the year ago fiscal year, it added.

The Board of Directors of the company has proposed a dividend of Rs 20 per share of face value Rs 2 each for the financial year 2020-21, Divi's Laboratories said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Divi's LaboratoriesQ4 Resultspharmaceutical firms

First Published: May 29 2021 | 9:49 PM IST

Next Story